Inventor
RIDDELL STANLEY R
US28 patents
⚠️ This page may combine multiple inventors who share the name “RIDDELL STANLEY R”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
HUTCHINSON FRED CANCER RES
12 patentsUS6040177AMar 21, 2000
High efficiency transduction of T lymphocytes using rapid expansion methods ("REM")
HUTCHINSON FRED CANCER RES593 citations98
US5827642AOct 27, 1998
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
HUTCHINSON FRED CANCER RES235 citations98
US10780118B2Sep 22, 2020
Method and compositions for cellular immunotherapy
HUTCHINSON FRED CANCER RES21 citations93
US10736918B2Aug 11, 2020
Method and compositions for cellular immunotherapy
HUTCHINSON FRED CANCER RES24 citations93
US10968275B2Apr 6, 2021
Anti-ROR1 antibodies and uses thereof
HUTCHINSON FRED CANCER RES17 citations88
US10869889B2Dec 22, 2020
Method and compositions for cellular immunotherapy
HUTCHINSON FRED CANCER RES8 citations83
US10494434B2Dec 3, 2019
Tagged chimeric effector molecules and receptors thereof
HUTCHINSON FRED CANCER RES10 citations81
US11065278B2Jul 20, 2021
Method and compositions for cellular immunotherapy
HUTCHINSON FRED CANCER RES3 citations72
US10653756B2May 19, 2020
Identification of CD8+ T cells that are CD161hi and/or IL18R(α)hi and have rapid drug efflux capacity
HUTCHINSON FRED CANCER RES2 citations71
US11046766B2Jun 29, 2021
Tagged chimeric effector molecules and receptors thereof
HUTCHINSON FRED CANCER RES2 citations70
US10828352B2Nov 10, 2020
Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
HUTCHINSON FRED CANCER RES6 citations69
US9931384B2Apr 3, 2018
Identification of CD8+ T cells that are CD161hi and/or IL18Rαhi and have rapid drug efflux capacity
HUTCHINSON FRED CANCER RES1 citations60
FRED HUTCHINSON CANCER CENTER
9 patentsUS12350312B2Jul 8, 2025
Methods for improving adoptive cell therapy
FRED HUTCHINSON CANCER CENTER0 citations60
US11993652B2May 28, 2024
Tagged chimeric effector molecules and receptors thereof
FRED HUTCHINSON CANCER CENTER0 citations59
US11932691B2Mar 19, 2024
Anti-ROR1 antibodies and uses thereof
FRED HUTCHINSON CANCER CENTER1 citations56
US11723962B2Aug 15, 2023
Cell-based neoantigen vaccines and uses thereof
FRED HUTCHINSON CANCER CENTER0 citations54
US12351618B2Jul 8, 2025
Engineered trimeric CD70 proteins and uses thereof
FRED HUTCHINSON CANCER CENTER0 citations50
US11845803B2Dec 19, 2023
Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
FRED HUTCHINSON CANCER CENTER0 citations49
US11827904B2Nov 28, 2023
Modified stem cells and uses thereof
FRED HUTCHINSON CANCER CENTER0 citations47
US11397183B2Jul 26, 2022
Biomarkers and uses thereof for selecting immunotherapy intervention
FRED HUTCHINSON CANCER CENTER0 citations45
US12398191B2Aug 26, 2025
BRAF-specific TCRs and uses thereof
FRED HUTCHINSON CANCER CENTER0 citations44